227 related articles for article (PubMed ID: 38191289)
1. Hemophagocytic lymphohistiocytosis following pembrolizumab and bevacizumab combination therapy for cervical cancer: a case report and systematic review.
Zhai C; Jin X; You L; Yan N; Dong J; Qiao S; Zhong Y; Zheng Y; Pan H
BMC Geriatr; 2024 Jan; 24(1):32. PubMed ID: 38191289
[TBL] [Abstract][Full Text] [Related]
2. Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the
Al-Samkari H; Snyder GD; Nikiforow S; Tolaney SM; Freedman RA; Losman JA
J Med Genet; 2019 Jan; 56(1):39-42. PubMed ID: 30287596
[TBL] [Abstract][Full Text] [Related]
3. Hemophagocytic lymphohistiocytosis with immunotherapy: brief review and case report.
Sadaat M; Jang S
J Immunother Cancer; 2018 Jun; 6(1):49. PubMed ID: 29871698
[TBL] [Abstract][Full Text] [Related]
4. Clinical characteristics, treatment, and management of pembrolizumab induced hemophagocytic lymphohistiocytosis.
Wang C; Sun W; Li Z; Wu T; Fang W
Invest New Drugs; 2023 Dec; 41(6):834-841. PubMed ID: 37897650
[TBL] [Abstract][Full Text] [Related]
5. Hemophagocytic Lymphohistiocytosis in a Patient with Rheumatoid Arthritis on Pembrolizumab for Lung Adenocarcinoma.
Akagi Y; Awano N; Inomata M; Kuse N; Tone M; Yoshimura H; Jo T; Takada K; Kumasaka T; Izumo T
Intern Med; 2020 Apr; 59(8):1075-1080. PubMed ID: 32009093
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related hemophagocytic lymphohistiocytosis due to atezolizumab: a case report and review of the literature.
Rubio-Perez J; Rodríguez-Perez ÁR; Díaz-Blázquez M; Moreno-García V; Dómine-Gómez M
J Med Case Rep; 2022 Oct; 16(1):365. PubMed ID: 36195892
[TBL] [Abstract][Full Text] [Related]
7. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
Noseda R; Bertoli R; Müller L; Ceschi A
J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
[TBL] [Abstract][Full Text] [Related]
8. Two cases of lung cancer with hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors.
Kurozumi A; Takahashi H; Watanabe T; Iwasaki Y
Thorac Cancer; 2021 May; 12(10):1625-1628. PubMed ID: 33783978
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitor-Induced Hemophagocytic Lymphohistiocytosis in a Patient With Squamous Cell Carcinoma.
Marar R; Prathivadhi-Bhayankaram S; Krishnan M
J Hematol; 2022 Aug; 11(4):142-147. PubMed ID: 36118548
[TBL] [Abstract][Full Text] [Related]
10. Hemophagocytic Lymphohistiocytosis Associated with Immunological Checkpoint Inhibitors: A Pharmacovigilance Study.
Diaz L; Jauzelon B; Dillies AC; Le Souder C; Faillie JL; Maria ATJ; Palassin P
J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902771
[TBL] [Abstract][Full Text] [Related]
11. Hemophagocytic Lymphohistiocytosis Secondary to Immune Checkpoint Inhibitor Therapy.
Rajapakse P; Andanamala H
World J Oncol; 2022 Apr; 13(2):49-52. PubMed ID: 35571340
[TBL] [Abstract][Full Text] [Related]
12. Clinical characterization of hemophagocytic lymphohistiocytosis caused by immune checkpoint inhibitors: a review of published cases.
Xu Z; Li H; Yu X; Luo J; Zhang Z
Hematology; 2024 Dec; 29(1):2340144. PubMed ID: 38606818
[TBL] [Abstract][Full Text] [Related]
13. Hemophagocytic lymphohistiocytosis associated with ocrelizumab treatment in a patient with multiple sclerosis.
Machlańska A; Helbig G; Chromik K; Zapała M; Zwiernik B; Selmaj K
Mult Scler; 2021 Oct; 27(11):1803-1805. PubMed ID: 33666121
[TBL] [Abstract][Full Text] [Related]
14. Hemophagocytic lymphohistiocytosis in two patients following treatment with pembrolizumab: two case reports and a literature review.
Wei Y; He W; Sun W; Wu C; Ren D; Wang X; Zhang M; Huang M; Ji N
Transl Cancer Res; 2022 Aug; 11(8):2960-2966. PubMed ID: 36093533
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab-induced Hemophagocytic Lymphohistiocytosis: an immunotherapeutic challenge.
Kalmuk J; Puchalla J; Feng G; Giri A; Kaczmar J
Cancers Head Neck; 2020; 5():3. PubMed ID: 32025343
[TBL] [Abstract][Full Text] [Related]
16. Hemophagocytic lymphohistiocytosis (HLH) and cytokine release syndrome (CRS) in a patient with oncogene-addicted metastatic non-small cell lung cancer (NSCLC) following combination chemotherapy-immunotherapy.
Heynemann S; Vanguru V; Adelstein S; Kao S
Asia Pac J Clin Oncol; 2024 Apr; 20(2):315-318. PubMed ID: 36562695
[TBL] [Abstract][Full Text] [Related]
17. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
18. Systemic inflammatory syndromes as life-threatening side effects of immune checkpoint inhibitors: case report and systematic review of the literature.
Liu LL; Skribek M; Harmenberg U; Gerling M
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36878533
[TBL] [Abstract][Full Text] [Related]
19. [Hemophagocytic lymphohistiocytosis caused by hematogenous disseminated pulmonary tuberculosis: A case report].
Li QY; Liang Y; Dai NN; Wang YX; Zhu BT; Wu R; Zhu H; Sun YC
Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Dec; 54(6):1219-1223. PubMed ID: 36533359
[TBL] [Abstract][Full Text] [Related]
20. Hemophagocytic lymphohistiocytosis: a review inspired by the COVID-19 pandemic.
Soy M; Atagündüz P; Atagündüz I; Sucak GT
Rheumatol Int; 2021 Jan; 41(1):7-18. PubMed ID: 32588191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]